George T. Kannarkat

LRRK2 levels in immune cells are increased in Parkinson’s disease

Darcie A. Cook, George T. Kannarkat, Amarallys F. Cintron et al. · npj Parkinson s Disease · 2017 · 288 citations · Full text

Common genetic variant association with altered HLA expression, synergy with pyrethroid exposure, and risk for Parkinson’s disease: an observational and case–control study

George T. Kannarkat, D A Cook, Jae‐Kyung Lee et al. · npj Parkinson s Disease · 2015 · 163 citations · Full text

Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice

Kathryn P. MacPherson, Pradoldej Sompol, George T. Kannarkat et al. · Neurobiology of Disease · 2017 · 147 citations · Full text

Inflammation, Neurodegenerative Diseases, Peripheral Administration +14

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson’s disease

Lori N. Eidson, George T. Kannarkat, Christopher J. Barnum et al. · Journal of Neuroinflammation · 2017 · 93 citations · Full text

Critical Role of Regulator G-Protein Signaling 10 (RGS10) in Modulating Macrophage M1/M2 Activation

Jae‐Kyung Lee, Jaegwon Chung, George T. Kannarkat et al. · PLoS ONE · 2013 · 84 citations · Full text

Immunology, Immune Regulation, Cd4 T Cell Responses +29